2-Cyanomethyl-2-carbethoxy-cyclohexanon | 42894-06-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 2-Cyanomethyl-2-carbethoxy-cyclohexanon
• 英文别名: Ethyl 1-(cyanomethyl)-2-oxocyclohexane-1-carboxylate
• CAS: 42894-06-4
• 化学式: C₁₁H₁₅NO₃
• 分子量: 209.245
• InChiKey: PMHFHSPCJVMCRY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.73
• 拓扑面积：
  67.2
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-Cyanomethyl-2-carbethoxy-cyclohexanon 在 potassium tert-butylate 作用下， 以 二甲基亚砜 为溶剂， 反应 3.0h， 以45%的产率得到2-氰基-3-氧代环庚烷-1-羧酸乙酯
  参考文献：
  名称：

  Xie, Zhuo-Feng; Suemune, Hiroshi; Sakai, Kiyoshi, Synthetic Communications, 1989, vol. 19, # 5and6, p. 987 - 992

  摘要：

  DOI：

文献信息

• N-ARYL AZASPIROALKENE AND AZASPIROALKANE COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF
  申请人：Bhatti Balwinder

  公开号：US20080242689A1

  公开（公告）日：2008-10-02

  Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are N-aryl or heteroaryl azaspiroalkene/alkane compounds, prodrugs or metabolites of these compounds, or pharmaceutically acceptable salts thereof. The aryl group can be a phenyl ring or a five- or six-membered heterocyclic ring (heteroaryl). The compounds and compositions can be used to treat and/or prevent a wide variety of conditions or disorders, particularly those disorders characterized by dysfunction of nicotinic cholinergic neurotransmission, including disorders involving neuromodulation of neurotransmitter release, such as dopamine release. CNS disorders, which are characterized by an alteration in normal neurotransmitter release, are another example of disorders that can be treated and/or prevented. The compounds and compositions can also be used to alleviate pain. The compounds can: (i) alter the number of nicotinic cholinergic receptors of the brain of the patient, (ii) exhibit neuroprotective effects and (iii) when employed in effective amounts, not result in appreciable adverse side effects (e.g., side effects such as significant increases in blood pressure and heart rate, significant negative effects upon the gastro-intestinal tract, and significant effects upon skeletal muscle).

  本发明揭示了化合物、包括这些化合物的药物组合物的制备方法和使用方法。这些化合物是N-芳基或杂芳基氮杂螺环烯/烷化合物、这些化合物的前药或代谢物，或其药学上可接受的盐。芳基可以是苯环或五元或六元杂环环（杂芳基）。这些化合物和组合物可用于治疗和/或预防各种疾病或疾病，特别是那些以尼古丁性胆碱能神经递质功能障碍为特征的疾病，包括涉及神经递质释放的神经调节疾病，如多巴胺释放。中枢神经系统疾病，其特征是正常神经递质释放的改变，是可以治疗和/或预防的另一个例子。这些化合物和组合物也可用于缓解疼痛。这些化合物可以：（i）改变患者的脑部尼古丁性胆碱能受体数量，（ii）表现出神经保护作用，（iii）当以有效剂量使用时，不会产生明显的不良副作用（例如，明显增加血压和心率、对胃肠道产生明显的负面影响以及对骨骼肌产生明显的影响等副作用）。
• XIE, ZHUO-FENG;SUEMUNE, HIROSHI;SAKAI, KIYOSHI, SYNTH. COMMUN., 19,(1989) N-6, C. 987-992
  作者：XIE, ZHUO-FENG、SUEMUNE, HIROSHI、SAKAI, KIYOSHI

  DOI：——

  日期：——
• HIGHLY ACTIVE CSF1R INHIBITOR COMPOUND
  申请人：ADLAI NORTYE BIOPHARMA CO., LTD.

  公开号：US20200399265A1

  公开（公告）日：2020-12-24

  The present invention relates to a CSF1R inhibitor, and in particular to a highly active CSF1R inhibitor compound having the structure of formula (I). Said compound of the present invention has high inhibitory activity on CSF1R.
• US7384929B2
  申请人：——

  公开号：US7384929B2

  公开（公告）日：2008-06-10
• US7754708B2
  申请人：——

  公开号：US7754708B2

  公开（公告）日：2010-07-13